Collaboration Aimed at Discovery and Development of Small Molecule Inhibitors Through to Phase I Proof of Mechanism in Metabolic Disorders Therapeutic Area
BENGALURU, Jan. 7, 2016 /CNW/ - Jubilant Biosys Ltd, a Bengaluru-based subsidiary of Jubilant Life Sciences Ltd, and Sanofi Deutschland GmbH, Frankfurt, Germany, announced a strategic alliance to discover and develop small molecule inhibitors for multiple targets in the metabolic disorders therapeutic area. The research alliance is aimed at developing therapeutic small molecules that will address the unmet needs in diabetes and obesity.
As per the terms of the agreement, Jubilant shall provide Sanofi integrated drug discovery and early development services across computational, synthetic chemistry, biology, GLP/ GMP services, to identify lead candidates and demonstrate clinical proof of mechanism in the metabolic disorders therapeutic areas. The research for the projects, which has been initiated, will be undertaken primarily at state-of-the-art R&D labs of Jubilant Biosys (Bengaluru, India) and Jubilant Chemsys (Noida, India).
Dr. Sriram Rajagopal, Chief Scientific Officer, Jubilant Biosys said: "We are excited to partner with Sanofi, one of the global healthcare leader, to offer our integrated drug discovery solutions. Over the past few years, we have been strengthening our therapeutic area expertise in the scientific perspective and this collaboration is a validation of our efforts. This alliance demonstrates Jubilant's commitment to global innovation and we look forward to a long mutually beneficial partnership."
Dr. Philip Just Larsen, Vice President, Global Head of Diabetes Research & Translational Medicine, Sanofi Deutschland GmbH said: "The collaboration with Jubilant underscores our commitment to engaging innovators around the world, as we develop the next generation of improved therapies for people with diabetes."
About Jubilant Biosys Ltd.:
Jubilant Biosys is a Bengaluru, India based subsidiary of Jubilant Life Sciences Ltd., an integrated global pharmaceutical and life sciences Company headquartered in Noida, India. Jubilant Biosys provides integrated drug discovery solutions to the global pharmaceutical industry. The Company has pioneered the risk shared collaborative discovery research model and demonstrated capabilities over the years through multiple partnerships with global pharmaceuticals firms in the therapeutic areas of oncology, metabolic disorders, pain & inflammation, CNS and others.
For more info: http://www.jubilantbiosys.com; http://www.jubl.com
SOURCE Jubilant Biosys Ltd
For further information: For Business Development, Dr. Rajiv Tyagi, Tel: +91-80-66628400, Email: Rajiv_Tyagi@jubilantbiosys.com